Analyzing Kyntra Bio (NASDAQ:KYNB) and CollPlant Biotechnologies (NASDAQ:CLGN)

Kyntra Bio (NASDAQ:KYNB) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kyntra Bio and CollPlant Biotechnologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2	0	5	0	2.43
CollPlant Biotechnologies	1	1	0	0	1.50

Kyntra Bio currently has a consensus target price of $36.80, indicating a potential upside of 717.78%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 3,100.00%. Given CollPlant Biotechnologies’ higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Kyntra Bio.

Earnings & Valuation

This table compares Kyntra Bio and CollPlant Biotechnologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44 million	2.83	$183.45 million	$45.30	0.10
CollPlant Biotechnologies	$2.37 million	2.99	-$11.49 million	($13.59)	-0.28

Kyntra Bio has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kyntra Bio and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

Risk and Volatility

Kyntra Bio has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Kyntra Bio beats CollPlant Biotechnologies on 9 of the 13 factors compared between the two stocks.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.